yttrium radioisotopes has been researched along with carboplatin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumenthal, RD; Goldenberg, DM; Leone, E; Modrak, D; Rodriguez, M | 1 |
| Belanger, R; Doolittle, ND; Haluska, M; Hedrick, NA; Jahnke, K; Lacy, CA; Nance, RW; Neuwelt, EA; Ryan, DA; Tyson, RM; Varallyay, C | 1 |
2 other study(ies) available for yttrium radioisotopes and carboplatin
| Article | Year |
|---|---|
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Topics: Antineoplastic Agents; Carboplatin; Cell Division; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Resistance, Neoplasm; Drug Synergism; Female; Genetic Therapy; Humans; In Vitro Techniques; Mutation; Ovarian Neoplasms; Paclitaxel; Radioimmunotherapy; Tetrazolium Salts; Thiazoles; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Yttrium Radioisotopes | 2004 |
Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Radioimmunotherapy; Yttrium Radioisotopes | 2007 |